Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Repligen

DB:RGN
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RGN
DB
$5B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Repligen Corporation develops and commercializes bioprocessing technologies and systems that are used in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
RGN Share Price and Events
7 Day Returns
3.4%
DB:RGN
1.7%
Europe Life Sciences
2.1%
DE Market
1 Year Returns
74.5%
DB:RGN
26.1%
Europe Life Sciences
-16.6%
DE Market
RGN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Repligen (RGN) 3.4% 10.4% 5.3% 74.5% 178.8% 198%
Europe Life Sciences 1.7% 1.6% 6.5% 26.1% 80.1% 179%
DE Market 2.1% -12.6% -22.9% -16.6% -21.9% -27.8%
1 Year Return vs Industry and Market
  • RGN outperformed the Life Sciences industry which returned 26.1% over the past year.
  • RGN outperformed the Market in Germany which returned -16.6% over the past year.
Price Volatility
RGN
Industry
5yr Volatility vs Market

RGN Value

 Is Repligen undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Repligen to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Repligen.

DB:RGN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 10 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:RGN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 0.94
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.941 (1 + (1- 21%) (5.02%))
0.985
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.99
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (0.985 * 5.44%)
4.97%

Discounted Cash Flow Calculation for DB:RGN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Repligen is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:RGN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 4.97%)
2020 41.46 Analyst x3 39.49
2021 71.46 Analyst x4 64.85
2022 86.17 Analyst x3 74.50
2023 126.23 Analyst x1 103.96
2024 168.90 Analyst x1 132.52
2025 200.10 Est @ 18.47% 149.56
2026 225.73 Est @ 12.81% 160.73
2027 245.71 Est @ 8.85% 166.67
2028 260.64 Est @ 6.08% 168.43
2029 271.43 Est @ 4.14% 167.10
Present value of next 10 years cash flows $1,227.00
DB:RGN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $271.43 × (1 + -0.39%) ÷ (4.97% – -0.39%)
$5,043.38
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $5,043.38 ÷ (1 + 4.97%)10
$3,104.80
DB:RGN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,227.00 + $3,104.80
$4,331.80
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,331.80 / 52.08
$83.17
DB:RGN Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:RGN represents 0.89366x of NasdaqGS:RGEN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.89366x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 83.17 x 0.89366
€74.33
Value per share (EUR) From above. €74.33
Current discount Discount to share price of €90.00
= -1 x (€90.00 - €74.33) / €74.33
-21.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Repligen is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Repligen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Repligen's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:RGN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $0.44
NasdaqGS:RGEN Share Price ** NasdaqGS (2020-04-07) in USD $100.71
Europe Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 52.89x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 16.83x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Repligen.

DB:RGN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:RGEN Share Price ÷ EPS (both in USD)

= 100.71 ÷ 0.44

227.39x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Repligen is overvalued based on earnings compared to the Europe Life Sciences industry average.
  • Repligen is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does Repligen's expected growth come at a high price?
Raw Data
DB:RGN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 227.39x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
33.2%per year
Europe Life Sciences Industry PEG Ratio Median Figure of 15 Publicly-Listed Life Sciences Companies 2.35x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.22x

*Line of best fit is calculated by linear regression .

DB:RGN PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 227.39x ÷ 33.2%

6.84x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Repligen is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Repligen's assets?
Raw Data
DB:RGN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $20.35
NasdaqGS:RGEN Share Price * NasdaqGS (2020-04-07) in USD $100.71
Europe Life Sciences Industry PB Ratio Median Figure of 41 Publicly-Listed Life Sciences Companies 3.87x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.45x
DB:RGN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:RGEN Share Price ÷ Book Value per Share (both in USD)

= 100.71 ÷ 20.35

4.95x

* Primary Listing of Repligen.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Repligen is overvalued based on assets compared to the Europe Life Sciences industry average.
X
Value checks
We assess Repligen's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Repligen has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

RGN Future Performance

 How is Repligen expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
33.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Repligen expected to grow at an attractive rate?
  • Repligen's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Repligen's earnings growth is expected to exceed the Germany market average.
  • Repligen's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:RGN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:RGN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 33.2%
DB:RGN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 15%
Europe Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 18.5%
Europe Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:RGN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:RGN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 693 1
2023-12-31 512 2
2022-12-31 427 121 65 4
2021-12-31 364 94 48 10
2020-12-31 311 84 33 10
2020-04-07
DB:RGN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 270 67 21
2019-09-30 253 55 23
2019-06-30 233 53 27
2019-03-31 210 41 21
2018-12-31 194 33 17
2018-09-30 184 42 23
2018-06-30 171 21 23
2018-03-31 155 18 29
2017-12-31 141 17 28
2017-09-30 125 4 21
2017-06-30 113 5 18
2017-03-31 110 12 13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Repligen's earnings are expected to grow significantly at over 20% yearly.
  • Repligen's revenue is expected to grow by 15% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:RGN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from Repligen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RGN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31 1.20 1.20 1.20 1.00
2022-12-31 1.09 1.21 0.97 2.00
2021-12-31 0.84 0.95 0.72 5.00
2020-12-31 0.59 0.67 0.47 5.00
2020-04-07
DB:RGN Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 0.44
2019-09-30 0.51
2019-06-30 0.60
2019-03-31 0.48
2018-12-31 0.38
2018-09-30 0.53
2018-06-30 0.53
2018-03-31 0.71
2017-12-31 0.74
2017-09-30 0.59
2017-06-30 0.52
2017-03-31 0.39

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Repligen is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Repligen's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Repligen has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

RGN Past Performance

  How has Repligen performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Repligen's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Repligen has delivered over 20% year on year earnings growth in the past 5 years.
  • Repligen's 1-year earnings growth exceeds its 5-year average (28.9% vs 25.9%)
  • Repligen's earnings growth has exceeded the Europe Life Sciences industry average in the past year (28.9% vs 6.3%).
Earnings and Revenue History
Repligen's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Repligen Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RGN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 270.25 21.41 91.61 19.45
2019-09-30 252.71 23.45 80.67 17.43
2019-06-30 232.80 26.58 71.90 15.60
2019-03-31 209.84 21.22 68.29 16.15
2018-12-31 194.03 16.62 62.76 15.82
2018-09-30 183.70 23.16 64.49 15.74
2018-06-30 170.75 23.03 63.63 14.14
2018-03-31 155.48 28.73 58.23 10.22
2017-12-31 141.24 28.35 51.51 8.67
2017-09-30 125.22 21.21 42.95 7.64
2017-06-30 113.32 17.69 33.82 7.53
2017-03-31 110.04 13.12 31.17 7.56
2016-12-31 104.54 11.68 30.85 7.36
2016-09-30 100.39 6.92 27.50 6.75
2016-06-30 95.53 8.30 27.59 6.35
2016-03-31 87.82 8.04 25.30 5.71
2015-12-31 83.54 9.35 24.70 5.74
2015-09-30 78.48 8.68 23.20 5.64
2015-06-30 73.95 7.61 20.89 5.80
2015-03-31 68.04 6.82 18.98 5.98
2014-12-31 63.55 8.17 16.34 5.61
2014-09-30 62.54 11.90 14.73 5.70
2014-06-30 66.08 16.32 13.98 5.48
2014-03-31 68.04 18.03 12.78 6.36
2013-12-31 68.17 16.09 12.70 7.34
2013-09-30 71.60 22.32 12.59 8.02
2013-06-30 67.88 18.24 12.81 9.02

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Repligen has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Repligen used its assets less efficiently than the Europe Life Sciences industry average last year based on Return on Assets.
  • Repligen's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Repligen's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Repligen has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

RGN Health

 How is Repligen's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Repligen's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Repligen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Repligen's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Repligen's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Repligen Company Filings, last reported 3 months ago.

DB:RGN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 1,059.77 232.77 528.39
2019-09-30 1,045.12 230.18 513.45
2019-06-30 878.97 105.70 208.89
2019-03-31 625.03 104.60 196.14
2018-12-31 615.57 103.49 193.82
2018-09-30 606.49 102.40 190.30
2018-06-30 598.66 101.33 175.61
2018-03-31 597.18 100.28 173.88
2017-12-31 591.55 99.25 173.76
2017-09-30 576.87 98.23 159.67
2017-06-30 190.94 97.23 144.95
2017-03-31 176.79 96.24 141.84
2016-12-31 168.76 95.27 141.78
2016-09-30 166.52 94.32 178.71
2016-06-30 163.72 93.38 181.80
2016-03-31 128.89 0.00 69.70
2015-12-31 122.75 0.00 71.77
2015-09-30 121.45 0.00 68.87
2015-06-30 118.22 0.00 63.17
2015-03-31 111.93 0.00 54.47
2014-12-31 111.73 0.00 58.45
2014-09-30 114.59 0.00 54.08
2014-06-30 115.56 0.00 50.03
2014-03-31 108.85 0.00 70.76
2013-12-31 103.89 0.00 61.62
2013-09-30 100.16 0.00 62.99
2013-06-30 92.45 0.00 58.15
  • Repligen's level of debt (22%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Repligen's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (28.9%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 10.5x coverage).
X
Financial health checks
We assess Repligen's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Repligen has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

RGN Dividends

 What is Repligen's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Repligen dividends.
If you bought €2,000 of Repligen shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Repligen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Repligen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:RGN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 12 Stocks 0.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.7%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:RGN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-07

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Repligen has not reported any payouts.
  • Unable to verify if Repligen's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Repligen's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Repligen has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Repligen's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Repligen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Repligen has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

RGN Management

 What is the CEO of Repligen's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tony Hunt
COMPENSATION $13,893,326
AGE 55
TENURE AS CEO 4.9 years
CEO Bio

Mr. Anthony J. Hunt, also known as Tony, has been the Chief Executive Officer and President of Repligen Corporation since May 21, 2015. Mr. Hunt served as Secretary of Repligen Corporation. He served as Chief Operating Officer of Repligen Corporation since May 6, 2014 until May 21, 2015. Mr. Hunt served as President of BioProduction at Life Technologies. He played a key role in the development and growth of Life Technologies's bioprocessing business, where he focused on expanding the upstream Gibco(R) cell culture franchise and building the downstream purification and analytics franchises. Mr. Hunt oversee commercial and manufacturing operations for Repligen. He joined Life Technologies in 2008, first as General Manager, BioProduction Chromatography and Pharma Analytics before being named President, BioProduction in 2011. In this most recent role, where he led an organization of approximately 200 employees, his responsibilities included commercial operations and research and development, as well as product management and marketing. Prior to this role, Mr. Hunt was with Applied Biosystems for eight years, served as Senior Director, Pharma Programs where he launched the pharma analytics business that in 2008 became a part of the bioproduction platform at Life Technologies. Mr. Hunt began his career with Repligen where he was involved in process development. He has been Director of Repligen Corporation since May 2015 and has been its Member of Scientific Advisory Board since March 2016. He received a Bachelors of Science degree in microbiology from University College Galway, Ireland, a Masters of Science degree in biotechnology from University College Galway, Ireland and a Masters of Business Administration from Boston University School of Management.

CEO Compensation
  • Tony's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.
  • Tony's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Repligen management team in years:

4.2
Average Tenure
56
Average Age
  • The tenure for the Repligen management team is about average.
Management Team

Tony Hunt

TITLE
CEO, President
COMPENSATION
$14M
AGE
55
TENURE
4.9 yrs

Jon Snodgres

TITLE
CFO & Secretary
COMPENSATION
$1M
AGE
53
TENURE
5.8 yrs

Ralf Kuriyel

TITLE
Senior Vice President of Research & Development
COMPENSATION
$1M
AGE
60
TENURE
3.5 yrs

Steve Curran

TITLE
Vice President of Global Operations

Sondra Newman

TITLE
Global Head of Investor Relations

Stephen Tingley

TITLE
Vice President of Sales
TENURE
3.3 yrs

Rachel Goodrich

TITLE
Vice President of Marketing
TENURE
3.1 yrs

Ken Elmer

TITLE
Global Head of Human Resources
TENURE
3.3 yrs

Tony MacDonald

TITLE
Senior Vice President of Ultrafiltration & Diafiltration
AGE
57
TENURE
16.3 yrs

Gustav Silfversparre

TITLE
Vice President of Operations - Repligen Sweden
TENURE
7.1 yrs
Board of Directors Tenure

Average tenure and age of the Repligen board of directors in years:

4.7
Average Tenure
66
Average Age
  • The tenure for the Repligen board of directors is about average.
Board of Directors

Karen Dawes

TITLE
Chairperson
COMPENSATION
$332K
AGE
67
TENURE
8.3 yrs

Tony Hunt

TITLE
CEO, President
COMPENSATION
$14M
AGE
55
TENURE
4.9 yrs

Glenn Cooper

TITLE
Independent Director
COMPENSATION
$195K
AGE
66
TENURE
10.7 yrs

Glenn Muir

TITLE
Independent Director
COMPENSATION
$215K
AGE
60
TENURE
4.5 yrs

Thomas Ryan

TITLE
Independent Director
COMPENSATION
$190K
AGE
77
TENURE
16.6 yrs

Alfred Goldberg

TITLE
Member of Scientific Advisory Board
COMPENSATION
$16K
AGE
76
TENURE
4.1 yrs

John Cox

TITLE
Director & Member of Scientific Advisory Board
COMPENSATION
$185K
AGE
56
TENURE
4.1 yrs

Nicolas Barthelemy

TITLE
Independent Director
COMPENSATION
$190K
AGE
53
TENURE
5.8 yrs

Charlie Cooney

TITLE
Member of Scientific Advisory Board
AGE
75
TENURE
4.1 yrs

Steven Cramer

TITLE
Member of Scientific Advisory Board
TENURE
4.1 yrs
Who owns this company?
Recent Insider Trading
  • Repligen individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
26. Mar 20 Sell John Cox Individual 24. Mar 20 24. Mar 20 -1,858 €89.59 €-166,461
05. Mar 20 Sell Jon Snodgres Individual 03. Mar 20 04. Mar 20 -1,655 €81.19 €-133,156
05. Mar 20 Sell Thomas Ryan Individual 03. Mar 20 03. Mar 20 -2,225 €76.87 €-171,025
05. Mar 20 Sell Anthony Hunt Individual 03. Mar 20 04. Mar 20 -14,490 €80.95 €-1,169,270
05. Mar 20 Sell Ralf Kuriyel Individual 03. Mar 20 04. Mar 20 -3,005 €81.73 €-243,992
27. Feb 20 Sell Ralf Kuriyel Individual 26. Feb 20 26. Feb 20 -195 €79.61 €-15,524
27. Feb 20 Sell Jon Snodgres Individual 26. Feb 20 26. Feb 20 -1,100 €79.85 €-87,183
26. Feb 20 Sell John Cox Individual 24. Feb 20 24. Feb 20 -4,455 €87.39 €-380,916
27. Feb 20 Sell Anthony Hunt Individual 26. Feb 20 26. Feb 20 -3,475 €79.85 €-276,366
24. Feb 20 Sell Karen Dawes Individual 21. Feb 20 21. Feb 20 -4,000 €93.04 €-363,447
11. Sep 19 Sell Anthony Hunt Individual 09. Sep 19 09. Sep 19 -12,094 €81.67 €-901,154
28. May 19 Sell Glenn Cooper Individual 23. May 19 23. May 19 -5,000 €60.47 €-299,737
X
Management checks
We assess Repligen's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Repligen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

RGN News

Simply Wall St News

RGN Company Info

Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems that are used in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA kits, which are analytical test kits to quantitate the proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber module-bag-tubing sets. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.

Details
Name: Repligen Corporation
RGN
Exchange: DB
Founded: 1981
$4,816,267,175
52,083,563
Website: http://www.repligen.com
Address: Repligen Corporation
Building 1,
Suite 100,
Waltham,
Massachusetts, 02453,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS RGEN Common Stock Nasdaq Global Select US USD 29. Apr 1986
DB RGN Common Stock Deutsche Boerse AG DE EUR 29. Apr 1986
BRSE RGN Common Stock Berne Stock Exchange CH CHF 29. Apr 1986
Number of employees
Current staff
Staff numbers
761
Repligen employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 20:59
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/04/03
Last earnings filing: 2020/02/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.